Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Royal Numico/Rexall

This article was originally published in The Tan Sheet

Executive Summary

Firms settle class action litigation with shareholders seeking to enjoin Rexall directors from proceeding with the merger (1"The Tan Sheet" May 8, pp. 3-4). The agreement calls for the firms to lower the maximum fee and expenses reimbursement payable by Rexall to Royal Numico in the event the merger falls through to $60 mil. from $79 mil., provide Rexall shareholders with appraisal rights related to the merger and confirm to stockholders the absence of any inquiries by third parties concerning possibly buying Rexall. Numico and Rexall have denied wrongdoing in the case, saying they entered into the settlement to avoid the expense and distraction of continued litigation

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS091264

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel